Valuation: CorMedix Inc.

Market Cap 617M 542M 504M 463M 870M 59.61B 883M 5.98B 2.34B 29.21B 2.32B 2.27B 101B P/E 2026 *
15.6x
P/E 2027 * 89.4x
Enterprise Value 617M 542M 504M 463M 870M 59.61B 883M 5.98B 2.34B 29.21B 2.32B 2.27B 101B EV / Sales 2026 *
1.85x
EV / Sales 2027 * 2.16x
Free-Float
92.47%
Yield 2026 *
-
Yield 2027 * -
1 day-2.24%
1 week-6.53%
Current month+0.25%
1 month+1.94%
3 months+6.06%
6 months+8.25%
Current year-32.33%
1 week 7.69
Extreme 7.69
8.53
1 month 7.5
Extreme 7.495
8.98
Current year 6.12
Extreme 6.125
12.29
1 year 6.12
Extreme 6.125
14.96
3 years 2.57
Extreme 2.57
17.43
5 years 2.57
Extreme 2.57
17.43
10 years 0.86
Extreme 0.8605
18.8
Manager TitleAgeSince
Chief Executive Officer 50 2022-05-09
Director of Finance/CFO 54 2025-08-28
Compliance Officer 66 2023-12-11
Director TitleAgeSince
Director/Board Member 67 2015-08-05
Chairman 81 2017-08-02
Director/Board Member 70 2011-08-15
Date Insider Type Main position Quantity % Market Cap.
2/4/26 Free

Chief Operating Officer

36,006 0.0457%
2/4/26 Free

Chief Executive Officer

77,156 0.0979%
2/4/26 Free

General Counsel

36,006 0.0457%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%-6.53%-31.51%+107.11% 617M
+0.45%+2.80%+54.73%+21.89% 324B
-0.07%+2.09%+23.58%-11.37% 68.88B
+1.35%+5.29%+40.68%+91.38% 9.72B
+0.93%-1.38%+2.01%-3.34% 8.37B
+1.13%+1.51%-21.44%-1.35% 4.32B
+4.90%+5.79%-38.81%+23.85% 3.83B
-4.00%+0.71%-5.66%+13.37% 3.62B
-2.10%-3.83%+37.58%+52.58% 2.68B
-4.07%-2.45%-8.03%-16.98% 2.04B
Average -0.37%+0.46%+5.31%+27.71% 42.78B
Weighted average by Cap. +0.36%+2.16%+45.71%+17.46%

Financials

2026 *2027 *
Net sales 335M 294M 273M 251M 471M 32.3B 479M 3.24B 1.27B 15.83B 1.26B 1.23B 54.76B 285M 250M 233M 214M 402M 27.54B 408M 2.76B 1.08B 13.5B 1.07B 1.05B 46.68B
Net income 47.14M 41.39M 38.5M 35.33M 66.41M 4.55B 67.43M 457M 179M 2.23B 177M 173M 7.72B 8.61M 7.56M 7.03M 6.45M 12.13M 831M 12.32M 83.38M 32.62M 407M 32.31M 31.62M 1.41B
Net Debt - -
Logo CorMedix Inc.
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Employees
191
Date Price Change Volume
26-07-24 US$7.870 -2.24% 625,290
26-07-23 US$8.050 +1.39% 698,511
26-07-22 US$7.940 -3.05% 860,115
26-07-21 US$8.190 +5.27% 1,038,432
26-07-20 US$7.780 -7.60% 1,156,381
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.870USD
Average target price
15.00USD
Spread / Average Target
+90.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRMD Stock